Literature DB >> 26730842

Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: Two-year results.

Meng Peng1, Wei Ji1, Xiongjing Jiang2, Hui Dong1, Yubao Zou1, Lei Song1, Huimin Zhang1, Weiguo Zhang3, Yuejin Yang1, Runlin Gao1.   

Abstract

OBJECTIVES: We aimed to investigate the long-term clinical outcomes of selective stenting versus percutaneous balloon angioplasty (PTA) in hypertensive patients with renal artery stenosis caused by Takayasu arteritis (RASTA).
METHODS: We retrospectively analyzed the data of consecutive 152 RASTA patients from Fuwai Hospital between 2005 and 2012. All target lesions of renal arteries were firstly treated by plain PTA. After angioplasty, if flow-limited dissection and/or residual stenosis >50% of diameter on angiogram existed, a selective stenting was then followed to further morphological improvement.
RESULTS: The baseline characteristics between PTA (n=93) and stenting groups (n=59) were indistinguishable. At two-year follow-up, the rates of normalized, improved, and unaltered hypertension were 27.4%, 63.4% and 12.3% in PTA group (n=93) versus 22.4%, 62.1% and 15.5% respectively in stenting group (p=0.79). Primary patency rate was 90.1% in renal arteries (125 lesions) treated with PTA versus 75.6% in renal arteries (64 lesions) treated with stent placement (p=0.008). Female, active stage of the disease requiring glucocorticoid and/or immunosuppressant agents, residual stenosis rate and stenting were significantly associated with the restenosis. In patients with restenosis, renal artery occlusion occurred more in stenting group (8/15), compared with that in PTA group (1/12) (p=0.019). The stenting group underwent more reintervention procedures than PTA group (13/63 versus 8/125, p=0.003).
CONCLUSIONS: If PTA alone failed in treating RASTA, selective stenting resulted in similarly effective blood pressure reduction. Stenting also resulted in lower 2-year primary patency rate, higher occlusion rate and higher reintervention rate than those who did not need stenting.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angioplasty; Clinical outcome; Hypertension; Renal artery stenosis; Stent placement; Takayasu arteritis

Mesh:

Year:  2015        PMID: 26730842     DOI: 10.1016/j.ijcard.2015.12.006

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  18F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations.

Authors:  Jiali Fan; Dongmei Wei; Huimin Zhang; Xiaoxin Sun; Jun Cai; Luyun Fan; Jiachen Yu; Wenjun Ma; Lei Song; Xianliang Zhou
Journal:  Clin Rheumatol       Date:  2020-06-19       Impact factor: 2.980

2.  Continuous infusion of lipo-prostaglandin E1 for Takayasu's arteritis with heart failure in an 11-month-old baby: a case report.

Authors:  Ryo Higaki; Aya Miyazaki; Yujiro Tajiri; Mikihito Shoji; Shun Saito; Shin-Ichiro Yoshimura; Naoki Miki; Kazuhiro Hatta; Hiraku Doi
Journal:  J Med Case Rep       Date:  2018-09-02

3.  Clinical course and prognostic factors of childhood Takayasu's arteritis: over 15-year comprehensive analysis of 101 patients.

Authors:  Luyun Fan; Huimin Zhang; Jun Cai; Lirui Yang; Bin Liu; Dongmei Wei; Jiachen Yu; Jiali Fan; Lei Song; Wenjun Ma; Xianliang Zhou; Haiying Wu; Ying Lou
Journal:  Arthritis Res Ther       Date:  2019-01-22       Impact factor: 5.156

Review 4.  Advances in Takayasu arteritis: An Asia Pacific perspective.

Authors:  Debashish Danda; Prathyusha Manikuppam; Xinping Tian; Masayoshi Harigai
Journal:  Front Med (Lausanne)       Date:  2022-08-15

5.  Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.

Authors:  Ana F Águeda; Sara Monti; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Bhaskar Dasgupta; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.